Powered by

-TESARO Enters Asset Purchase Agreement with TerSera Therapeutics LLC for VARUBI in the U.S. and Canada

Jul 03, 2018 - ENP Newswire

WALTHAM - TESARO, Inc.(NASDAQ: TSRO), an oncology-focused biopharmaceutical company, today announced that it has entered into an asset purchase agreement with TerSera Therapeutics LLC(TerSera) under which it will divest North American rights to the oral and intravenous formulations of VARUBI (rolapitant).

TerSera will be responsible for VARUBI in the U.S. and Canada, and TESARO will continue to commercialize VARUBY in Europe and will retain rest of world rights under a sublicense from TerS...